NicOx
15
0
0
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
6.7%
1 terminated/withdrawn out of 15 trials
93.3%
+6.8% vs industry average
20%
3 trials in Phase 3/4
0%
0 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)
Role: lead
ADenoVirus Initiative Study in Epidemiology in Italy
Role: lead
ADenoVirus Initiative Study in Epidemiology in Germany
Role: lead
ADenoVirus Initiative Study in Epidemiology in Spain
Role: lead
ADenoVirus Initiative Study in Epidemiology in UK
Role: lead
ADenoVirus Initiative Study in Epidemiology in France
Role: lead
Pharmacokinetics Study: Determination of Naproxcinod and Its Metabolites After Oral Administration in Male
Role: lead
Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee
Role: lead
Analgesic Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee
Role: lead
To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension
Role: lead
A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure
Role: lead
Effect of Repeated Dosing of Naproxcinod on Renal Hemodynamic and on Sodium Balance in Healthy Volunteers Before and After a Single Dose of Furosemide
Role: lead
A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects
Role: lead
Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip
Role: lead
A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function
Role: lead
All 15 trials loaded